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During treatment for malignant disease with antimetabolites a few instances of photo-
sensitivity have been reported. This phenomenon was studied experimentally in patients re-
ceiving methotrexate for psoriasis. An acute dermal inflammation was elicited through re-
peated exposure to ultraviolet light during the days preceding a single intravenous injection
of the drug.
When ultraviolet light was given four days before methotrexate, or simultaneously with
the injection, the regular rise and slope of inflammatory intensity was registered in the skin.
When ultraviolet light was given one or two days before the inj ection of methotrexate the
drug influenced the course of inflammation towards a diphasic curve. Thus, methotrexate
when administered in proper time reactivates a receding inflammatory process.
It is concluded that exacerbations of irradiation erythema in patients on cancer chemo-
therapy provide examples of "false photosensitivity".
The signs of acute inflammation in human
skin include vasodilatat.ion with increased perme-
ability leading to erythema and edema, and
cellular infiltration. With some variation in
time sequence these signs occur regardless of
the type of eliciting agent, thermal or chemical
injury, microbial infection, ultraviolet light
(UV) or other irradiation. The intensity of the
inflammatory reaction usually reaches a peak
within a couple of hours, then recedes slowly
during several days. The course and intensity
of acute inflammation may be shortened or
modified with different drugs, e.g. salicylates,
antihistamines, and corticosteroids. The present
study, together with clinical observations, in-
dicates that a group of drugs, the antimetabo-
lites, is capable of changing the course of an
acute irradiation dermatitis, this being reacti-
vated after an initial recession.
CASE REPORT
A female aged 31 years was observed with a
diagnosis of ehoriocarcinoma uteri; hysterectomy
had been performed one month earlier. She had
been given repeated combined courses of metho-
trexate® 20 mg per day and 6-mercaptopurine 200
mg per day, last course starting on "Day 2". She
had exposed herself to the sun on Day 1 with
consequent slight erythema, disappearing normally
on Days 2 and 3. Without further sun bathing the
erythema recurred on exposed areas on Day 4.
During the following few days it developed into
an intense dermatitis with a dusky red infiltration
including flaccid, confluent bullae. In essence, the
patient experienced a second degree irradiation
injury. She had a slight granuloeytopenia. The
exaggerated sun burn subsided during the next
week under topical steroid therapy.
Stimulated by this observation an attempt was
made to mimic the clinical situation by studying
the influence of methotrexate on experimental
ultraviolet light inflammation in human skin.
EXPERIMENTAL
Five patients with a discoid type of psoriasis
were chosen for the study. There were three
males and two females, ages 41—67 years. The
disease was refractory to regular topical rem-
edies and, thus, treatment with methotrexate
was planned. Methotrexate® was given in a
single intravenous injection of 50 mg (in one
patient 25 mg only). Before treatment, as well
as at three days after the injection, a complete
blood count., serum creatinine and trans-
aminases were performed. No pathologic
changes were observed.
An acute localized inflammation was pro-
duced in the uninvolved skin of the back of
each patient with a single exposure from a
Kromayer high-pressure water-cooled mercury
are lamp. This light source emits a multilinear
spectrum within the wave-length range of
2480—4360 A with highest emission at 3020,
3130, 3660, 4050, and 4360 A. The lamp is
usually applied in immediate contact with the
skin. However, for quantitation purposes, it
was desired to reduce the intensity of the UV
reaction. Therefore, the contact surface was
diminished and the source/skin distance in-
creased by means of a circular tube adapted to
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FIG. 1. Scheme of TJVL exposure. Within circles
irradiation time is given in seconds. Numbers 0—4
indicate days before methotrexate injection.
tile light source opening. The length of the tube
was 65 mm, its diameter 10 mm. No filter was
used.
The skin of the back was irradiated for 10,
20 and 40 seconds in a separate vertical row
on each of five consecutive days (Fig. 1). On
the last day the patient was injected with
methotrexate. The intensity of the UV reactions
was estimated daily, and followed up to one
week after the injection. The reactions were
given 10 points for erythema without infiltra-
tion, 20 points for erythema with infiltration,
and 30 points for an infiltrated lesion extending
outside the irradiated spot. Mean values were
calculated from the accumulated points ob-
tained in the identical situation of each patient
and illustrated graphically.
RESULTS
In the five patients treated with metho-
trexate a regular rise and fall of the intensity
of inflammation induced by TJV could be
demonstrated. This occurred when the inflam-
matory stimulus was applied four days before
injection of the drug, and when it was given
on the same day as the drug. This course of
events may be seen in figs 2A and E for a
low-grade stimulus, and in figs 3A and E for a
high-grade stimulus.
In the acute inflammation induced with UV
at one, two, and possibly three days before the
injection of methotrexate the regular course
was considerably changed (Fig. 2B—D and
Fig. 3B—D). A peak intensity of inflammation
was normally reached on the first day after ir-
radiation, and the curve started to slope. Then,
however, at two days after the injection of
methotrexate, the signs of acute inflammation
were reactivated. This second peak is illus-
trated in the photo (Fig. 4), where the UV
reaction induced at a later date has already
receded. The reactivation phenomenon was ob-
served in all patients studied, both with a low-
grade and a high-grade stimulus (Figs. 2 and 3,
resp.). Thus, a diphasic curve of inflammatory
intensity was obtained when the stimulus was
applied at. a proper time before the injection
of methotrexate. In some instances the second,
reactivated part of the inflammation was even
more intense than the first, regularly occurring
one (Fig2D).
DISCUSSION
The origin of the present study was a severe
sunburn in a patient treated with antimetabo-
lites. The initial erythema had subsided, but
recurred as a consequence of the treatment.
Only a few similar observations have been pre-
viously reported during chemotherapy with re-
lated compounds. Farber (1) described how
actinomycin D, given after small doses of radio-
therapy, induces an erythema in cases where
radiotherapy alone has no effect on the skin.
Sears (2) reported on three patients with
malignant disease in which hydroxyurea reac-
tivated a previously healed irradiation cry-
thema. Vogler et al. (3) observed a patient on
methotrexate with a severe erythema confined
to the exposed areas developing five days after
starting the treatment and seven days after sun
exposure. (The case seems identical with that
of the present work.) They also saw a patient
acquire a severe sunburn following a short ex-
posure while receiving methotrexate. Vogler et
al. interpreted the cutaneous reactions as ex-
amples of photosensitization to methotrexate
and thereafter admonished patients to stay out
of the sun. This warning is clearly warranted.
However, since the drug in the above-men-
tioned patients was administered after irradia-
tion, in some cases with an interval of several
days, this constitutes, not a genuine, but a
"false photosensitivity".
Instead, an influence of the drug in question
on the acute inflammation induced by the ir-
radiation could be suspected. The present study
using experimental dermatitis in human skin as
a model has indeed confirmed the potency of
methotrexate to reactivate the subsiding in-
flammatory process. Thus, the clinical situation
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FIG. 2. Inflammatory response to 20 seconds of ultraviolet light during seven consecutive
days, the intensity given in arbitrary units (see text). Each point is the mean intensity in
five subjects; vertical bars indicate standard error of the mean. In series A methotrexate(M) was inj ected four days after UV irradiation, in series B three days, in series C two
days, in series D one day, and in series E simultaneously with the irradiation.
FIG. 3. Same experiments as in Fig. 2, using 40 seconds of UVL.
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Fin. 4. Photo of the back skin of one subject, taken three days after methotrexate injec-
tion. The youngest IJY reactions in the vertical row on the far right have subsided, while
those elicited earlier (second and third row from right) are reactivated.
for one of the drugs named has been repro-
duced.
The specificity of drug action cannot be con-
cluded from the present work. The clinical ob-
servations, however, deal with three chemically
unrelated compounds: methctrexate, actinomy-
cm D and hydroxyurea. Probably, the common
antimetabolic activity is responsible for their
potency to influence acute irradiation derma-
titis.
It is not known if this reactivation phe-
nomenon may be demonstrated in every type
of inflammatory response. In the case reports
referred to above, irradiation both from x-rays
and from sun exposure was incriminated. In
the present investigation the stimulus of [V
was chosen for closest resemblance of the clini-
cal observations and other types of inflamma-
tory agents have not ben studied.
An untoward and unexpected flare-up of the
cutaneous inflammation observed during ami-
noptcrin® treatment of psoriasis (4) might
provide an example of an analogous reaetiva-
tion capacity of an antimetabolite. A paradoxi-
cal influence on the inflammatory reaction in
delayed allergy was reported for eyelophos-
phamide, an alkylating agent (5). This eyto-
toxic drug, when given as pretreatment before
sensitization to DNCB in the guinea pig, en-
hances the final challenge response. However,
with this reverse drug/inflammation time se-
quence the effect is probably of different nature.
Antimetabolie drugs exhibit a suppressive
action on the inflammatory signs of clinical and
experimental immune reactions. It has been
possible to differentiate the immuno-suppressive
effect from a specific anti-inflammatory po-
tency of these drugs (6—10). Thus, when acute
inflammation is inhibited by methotrexate or
6-mereaptopurine, this action goes parallel with
a failure of the mononuclear cell response in
the inflammatory site. At the same time, as
shown on human skin by skin window technic,
levels of grnnulocytes and lymphocytes in pe-
ripheral blood are unimpaired (8). In the five
patients of the present material no suppressive
V
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action on the circulating leukocytes by metho-
trexate was observed, although given in a dose
sufficient to ameliorate their skin disease. Nor
did methotrexate show an anti-inflammatory
effect on the developing IJY lesion when in-
jected at irradiation day.
Instead, the experiments have demonstrated
a hitherto unknown effect of methotrexate and,
presumably, of related compounds: the potency
to reactivate a receding UV inflammation. The
mechanism of this action is quite obscure. Nitta
(11) produced experimental inflammation of
different types in rabbit skin and reactivated
the original dermatitis by means of intrale-
sional injections of reduced glutathionc. Simul-
taneously, an increased protease activity in the
reactivated inflammations was found. Could
these proteases have been released as a con-
sequence of labilization or rupture of lysosomal
membranes? It is not known if methotrexate
and other antimetabolites should be added to
the list of inflammation-promoting compounds
acting by way of disrupting lysosomes cud
thereby liberating vasoactive proteolytic en-
zymes (12).
Finally, the possibility of methotrexate in-
terrupting the regular repair process should be
considered. The tensile strength of healing
wounds is significantly depressed by the drug
(13), an influence which might contribute to
the reactivation phenomenon. Since, however,
the second peak of inflammatory reaction in
several instances was higher than the first one a
solely inhibitory effect of methotrexate may be
excluded.
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